GlassScriptPhysician profile
Jacob R Miller
NPI 1922100650
$4,898.16
in general payments reported to CMS, 2019-2025
26 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $257 · 2021: $246 · 2022: $689 · 2023: $789 · 2024: $713 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,012 · Education: $18.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,011.58 |
| Education | $18.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $754.02 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $592.24 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Abbvie INC. | $521.14 | 2022-2025 | |
| Allergan, INC. | $477.56 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $393.47 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $308.18 | 2023-2025 | Tryptyr, Rocklatan, Clareon |
| Horizon Therapeutics Plc | $248.78 | 2019-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $206.99 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $173.46 | 2019-2021 | |
| Glaukos Corporation | $160.49 | 2025 | Idosetr |
| Sight Sciences, INC. | $156.73 | 2022-2025 | Omni Surgical System |
| Lumenis, INC | $114.86 | 2019 | |
| Oyster Point Pharma, INC. | $114.14 | 2022-2025 | Tyrvaya, Ryzumvi |
| Amgen INC. | $110.55 | 2024-2025 | Tepezza |
| Dompe US, INC. | $100.72 | 2019-2025 | Oxervate |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $91.04 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $82.69 | 2021-2022 | |
| Thea Pharma INC. | $77.51 | 2023-2025 | Iyuzeh |
| Astellas Pharma US INC | $42.58 | 2023-2024 | Izervay |
| Shire North American Group INC | $42.24 | 2019 | |
| Biotissue Holdings INC. | $39.31 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $24.70 | 2025 | Acthar |
| Travere Therapeutics, INC. | $19.86 | 2023 | Cholbam |
| Tearlab Corp | $15.89 | 2023 | Tearlab Osmolarity System |
| Akorn Operating Company LLC | $14.92 | 2021 | |
| Harrow Eye, LLC | $14.09 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.